NCT03552601 is a NA clinical trial of traditional speed in Fluid Loss, sponsored by Qingdao University.

Who is sponsoring NCT03552601?

NCT03552601 is sponsored by Qingdao University.

What drugs are being tested in NCT03552601?

Interventions in NCT03552601: traditional speed, faster speed.

What condition does NCT03552601 study?

NCT03552601 studies Fluid Loss.

Is NCT03552601 still recruiting?

NCT03552601 is currently status unknown. Last updated 28 August 2019.

Last reviewed 2019-08-28 · How we verify

NCT03552601

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Negatively Fluid Balancing Speed for ICU Patients With Acute Respiratory Distress Syndrome

Status unknown NA Last updated 28 August 2019

What this trial tests

NA trial testing traditional speed in Fluid Loss in 70 participants. Status unknown.

Timeline

1 August 2018

Primary endpoint
1 December 2020

30 December 2020

Quick facts

Lead sponsor	Qingdao University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	1 August 2018
Primary completion	1 December 2020
Estimated completion	30 December 2020
Sites	1 location across China

Drugs / interventions tested

traditional speed
faster speed

Conditions studied

Fluid Loss — all drugs for Fluid Loss →

Sponsor

Qingdao University

Who can join

18 and older, any sex, with Fluid Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Previous studies have shown that a positive fluid balance was an independent factor of worse prognosis in ICU patients with acute respiratory distress syndrome (ARDS), and negative fluid balance has been demonstrated to increase oxygenation index, reduce time under mechanical ventilation and ICU length of stay with no noticeable adverse effects. But there is no evidence that faster speed of negative fluid balance would be more beneficial for ARDS patients. So researchers designed the study to prove the effect of negatively fluid balancing speed for ICU patients with ARDS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Qingdao University trials

Trials by the same sponsor.

NCT06359977 — The Effect of Quantitative EEG Combined With Ultrasound and Sputum Volume on Predicting Weaning Failure · not yet recruiting
NCT06083831 — The Effect of Sequential Feeding for Circadian Rhythm and Gut Flora Rhythm in Critically Ill Patients · unknown
NCT05842993 — Study of Hydrogen Inhalation Compared With Placebo in Type 2 Diabetes Patients · NA · unknown
NCT05905588 — Study of Hydrogen-rich Water Compared With Placebo in Type 2 Diabetes Patients · NA · unknown
NCT04443335 — Comparison of Continuous Feeding and Sequential Feeding on Gut Microbiota and Metabolomics in Critically Ill Patients · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03552601 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qingdao University
Last refreshed: 28 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03552601.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing